Sequencing considerations in the third-line treatment of metastatic colorectal cancer

Am J Manag Care. 2024 May;30(2 Suppl):S31-S35. doi: 10.37765/ajmc.2024.89546.ABSTRACTNumerous advances in the standard of care for metastatic colorectal cancer (mCRC), including the approval of several new treatments indicated for treatment in the third line or later (3L+), have been made, yet data and appropriate guidance on the optimal sequencing and treatment strategies for these lines of therapy are lacking. Four treatments-regorafenib, trifluridine/tipiracil alone or with bevacizumab, and fruquintinib-are FDA-approved and recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of mCRC in the 3L+. When considering sequencing of treatment options for patients in the 3L+, the goal of treatment is to improve survival, but also maintain quality of life, a goal that requires consideration of relative efficacy and cumulative toxicity such as persistent myelosuppression.PMID:38701364 | DOI:10.37765/ajmc.2024.89546
Source: The American Journal of Managed Care - Category: Health Management Authors: Source Type: research